Please login to the form below

Not currently logged in
Email:
Password:

Michael Fleming joins biosimilars firm Coherus

He has experience at Elan, Genentech and GSK

Coherus Biosciences has named Michael Fleming as senior VP, commercial strategy.

Fleming was most recently at Elan where he was head of commercial and of the company's Tysabri (natalizumab) franchise.

He joins Coherus as it begins to advance its pipeline of biosimilars towards commercialisation, a process that has already seen it sign an alliance with Baxter to develop a biosimilar version of Amgen and Pfizer's big-selling arthritis and psoriasis drug Enbrel (etanercept).

“Michael's experience in building commercial operations and his knowledge of markets and health systems are of immediate importance,” said Danny Lanfear, CEO of Coherus.

“He will play a key role in defining strategies that effectively maximise the commercial potential of our products.”

Fleming gained experience in commercialising biological medicines during his time leading the strategy for Elan's multiple sclerosis drug Tysabri.

His other experience includes senior commercial roles at GlaxoSmithKline, Genentech, Nuvelo, Agendia and Campbell Alliance.

1st May 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics